ES2672472T3 - Composición farmacéutica que comprende ivabradina amorfa - Google Patents
Composición farmacéutica que comprende ivabradina amorfa Download PDFInfo
- Publication number
- ES2672472T3 ES2672472T3 ES14792774.3T ES14792774T ES2672472T3 ES 2672472 T3 ES2672472 T3 ES 2672472T3 ES 14792774 T ES14792774 T ES 14792774T ES 2672472 T3 ES2672472 T3 ES 2672472T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutically acceptable
- ivabradine
- cyclodextrin
- composition according
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
WOPCT/EP2013/076429 | 2013-12-12 | ||
EP2013076429 | 2013-12-12 | ||
PCT/EP2014/072524 WO2015001133A1 (fr) | 2013-12-12 | 2014-10-21 | Composition pharmaceutique comprenant de l'ivabradine amorphe |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2672472T3 true ES2672472T3 (es) | 2018-06-14 |
Family
ID=51845386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14792774.3T Active ES2672472T3 (es) | 2013-12-12 | 2014-10-21 | Composición farmacéutica que comprende ivabradina amorfa |
Country Status (3)
Country | Link |
---|---|
ES (1) | ES2672472T3 (fr) |
MX (1) | MX363389B (fr) |
WO (1) | WO2015001133A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015145234A1 (fr) * | 2014-03-27 | 2015-10-01 | Laboratorio Chimico Internazionale S.P.A. | Adsorbats d'ivabradine |
GB201621771D0 (en) * | 2016-12-20 | 2017-02-01 | Biogena (A P I) Ltd | New salts of compounds and uses thereof |
EP3366282A1 (fr) * | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Compositions pharmaceutiques orales solides d'ivabradine |
TR201703066A2 (tr) * | 2017-02-28 | 2018-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari |
CN109875969B (zh) * | 2019-03-19 | 2021-02-09 | 扬子江药业集团北京海燕药业有限公司 | 一种稳定的盐酸伊伐布雷定片剂及其制备方法 |
CN115770248B (zh) * | 2022-12-07 | 2023-08-04 | 郑州大学第一附属医院 | 一种盐酸伊伐布雷定制剂及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681862B1 (fr) | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
FR2868777B1 (fr) | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
PT1793862E (pt) * | 2004-08-02 | 2011-04-08 | Chiesi Farma Spa | Processo para a preparação de um composto de inclusão de piroxicam:beta-ciclodextrina |
FR2882556B1 (fr) | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882555B1 (fr) | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882554B1 (fr) | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882553B1 (fr) | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891827B1 (fr) | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891826B1 (fr) | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
RU2473544C2 (ru) | 2007-05-30 | 2013-01-27 | Инд-Свифт Лабораториз Лимитед | Способ получения ивабрадина гидрохлорида и его полиморфных модификаций |
CN101597261A (zh) | 2008-06-06 | 2009-12-09 | 北京深蓝海生物医药科技有限公司 | 无定形盐酸伊伐布雷定 |
CN101463008A (zh) | 2009-01-11 | 2009-06-24 | 山东鲁抗辰欣药业有限公司 | 盐酸伊伐布雷定无定型物及其制备方法 |
CN101559228B (zh) * | 2009-06-01 | 2011-05-18 | 石药集团欧意药业有限公司 | 一种治疗高脂血症合并慢性稳定型心绞痛的药物组合物 |
SI2902384T1 (en) | 2010-02-12 | 2018-03-30 | Krka, D.D., Novo Mesto | The form of ivabradine hydrochloride |
CA2800442C (fr) | 2010-06-14 | 2018-05-22 | Ratiopharm Gmbh | Composition pharmaceutique contenant de l'ivabradine a liberation modifiee |
EP2589594A1 (fr) | 2011-11-04 | 2013-05-08 | Urquima S.A. | Forme IV d'hydrochlorure d'ivabridine |
WO2014161131A1 (fr) * | 2013-04-01 | 2014-10-09 | Arissa Pharma | Préparation d'un complexe d'inclusion de méloxicam-β-cyclodextrine amorphe par l'intermédiaire d'un procédé de séchage par atomisation |
CN103393611B (zh) * | 2013-08-06 | 2015-08-19 | 南京正大天晴制药有限公司 | 一种盐酸伊伐布雷定片剂及其制备方法 |
-
2014
- 2014-10-21 WO PCT/EP2014/072524 patent/WO2015001133A1/fr active Application Filing
- 2014-10-21 ES ES14792774.3T patent/ES2672472T3/es active Active
- 2014-10-21 MX MX2016007682A patent/MX363389B/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016007682A (es) | 2016-09-09 |
MX363389B (es) | 2019-03-20 |
WO2015001133A1 (fr) | 2015-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2672472T3 (es) | Composición farmacéutica que comprende ivabradina amorfa | |
US11007152B2 (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant | |
KR101359327B1 (ko) | 리팍시민의 안정한 다형체 형태를 얻기 위한 폴리올의 용도 | |
HRP20191104T1 (hr) | Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu | |
AU2005206063B2 (en) | Method of preparing low-crystallinity oltipraz or amorphous oltipraz | |
BRPI0917807A2 (pt) | formulação sólida estável de um polipeptídeo agonista de recepto gc-c adequada para administração oral | |
US20100016378A1 (en) | Method of preventing dihydropyridine compound from degradation | |
US20170368048A1 (en) | Pharmaceutical Composition Comprising Amorphous Lenalidomide | |
WO2016097011A1 (fr) | Composition pharmaceutique comprenant de l'agomélatine amorphe | |
ES2471076T3 (es) | Compuestos de inclusión de silodoxina-ciclodextrina | |
US11517569B2 (en) | Vilazodone inclusion complexes, compositions and preparation thereof | |
US10471156B2 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
KR100783286B1 (ko) | 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물 | |
US9050326B2 (en) | Amido derivatives-contained pharmaceutical composition | |
EP3079702B1 (fr) | Composition pharmaceutique comprenant de l'ivabradine amorphe | |
US20080255231A1 (en) | Polymorphs of rivastigmine hydrogentartrate | |
WO2020111089A1 (fr) | Composition pharmaceutique | |
AU2013250251B2 (en) | Encapsulated formulation | |
Kumar et al. | Solid dispersions: An approach to enhance solubility of poorly soluble drugs | |
WO2020064188A1 (fr) | Composition pharmaceutique comprenant des dispersions solides de cladribine amorphe et un excipient hydrosoluble pharmaceutiquement acceptable | |
Giri et al. | Carriers used for the development of solid dispersion for poorly watersoluble drugs | |
KR100805675B1 (ko) | 클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법 | |
WO2008125134A1 (fr) | Procédé de préparation d'adsorbats de périndopril-tert-butylamine | |
KR100673558B1 (ko) | 사이클로덱스트린 또는 이의 유도체와 부틸프탈리드의 내포 착물, 이들의 제조 방법 및 용도 | |
Samsodien | Supramolecular derivatives of selected bioactive compounds: a physicochemical study |